Conference Reports for NATAP

Back

Feb 2009 Hong Kong 19th APASL- Conference of the Asian Pacific Association for the Study of the Liver 2009     Quantitative HBsAg for early prediction of response to PEGASYS therapy in patients with HBeAg-negative disease - (03/12/09)   Histologic Assessment of Long-term Entecavir (ETV) Treatment in Chronic Hepatitis B (CHB) Patients - (03/12/09)   HBsAg Clearance Continues to Increase After the End of Treatment With PEGASYS ± Lamivudine: 5-year Follow-up Study in Patients with HBeAg-Negative Disease - (03/12/09)   HBsAg Decline in Patients Treated With PEGASYS and its Association with Post-treatment Response in HBeAg-Positive Chronic Hepatitis B - (03/12/09)   PEGASYS But Not Adefovir Results in Significant Decline in HBsAg in Chinese Patients with HBeAg-Positive Disease Harboring Lamivudine-Resistant YMDD Mutations - (03/12/09)   Use of the Elecsys® HBsAg II assay for simple and accurate quantification of HBsAg levels in sera of patients infected with HBV - (03/12/09)   Evaluation of Long-term Entecavir (ETV) Treatment in Chronic Hepatitis B (CHB) Patients Switched from 24-week Lamivudine (LVD) Therapy - (03/11/09)